Nephrotoxicity Study

• Use cisplatin for a rodent nephrotoxicity model, with published regimens including a single intraperitoneal 10 mg/kg dose followed by sampling on days 1, 2, 3, 5, and 7;
• 1 mg/kg/day dosing for 1-14 days;
• And 1-10 mg/kg intraperitoneal dosing with analysis at 48 h.

• Gentamicin is supported as an aminoglycoside nephrotoxicity model at 80 mg/kg intraperitoneally for 8 days or 50-100 mg/kg/day for up to 7 days.

• Acetaminophen has been used at 1,000 mg/kg to induce acute renal injury in rats.

• Use assay kits or validated immunoassays for serum creatinine, BUN, urinary KIM-1, NGAL, clusterin, osteopontin, cystatin C, IL-18, nephrin, urinary protein, glucose, and alkaline phosphatase when those endpoints match the selected model.

• Use antibodies for renal KIM-1, NGAL, clusterin, Oat5, IL-18, cystatin C, and nephrin for immunohistochemistry or Western blotting when tissue biomarker localization or protein expression is required.

• Use metabolic cages or equivalent urine-collection systems for urinary biomarker analysis, centrifugation and clinical chemistry equipment for blood and urine analytes, histology processing equipment for kidney tissue sections, microscopy for renal lesion scoring, and Western blot or immunohistochemistry platforms for tissue biomarker detection.

• Randomize animals into vehicle-control and nephrotoxicant-treated groups, and include recovery or intervention groups only when the experimental question requires them.

• Collect baseline urine or blood when longitudinal biomarker comparison is planned, because urinary biomarkers and conventional chemistry markers have been compared across time after cisplatin, gentamicin, and acetaminophen exposure.

• Prepare cisplatin, gentamicin, or acetaminophen according to the selected published model, and select sampling times based on the expected injury window.

• Cisplatin models reported early biomarker changes before or around day 3, delayed BUN/creatinine increases around day 5 in one repeated-dose rat model, and dose-related urinary Oat5 changes at 48 h.

• Administer the selected nephrotoxicant using a literature-supported dosing route and schedule: cisplatin intraperitoneally at 10 mg/kg with sampling on days 1, 2, 3, 5, and 7;
• Cisplatin at 1 mg/kg/day for 1-14 days;
• Cisplatin at 1, 2, 5, or 10 mg/kg intraperitoneally with 48 h analysis;
• Gentamicin at 80 mg/kg intraperitoneally for 8 days;
• Gentamicin at 50 or 100 mg/kg/day for up to 7 days;
• Or acetaminophen at 1,000 mg/kg in rats.

• Collect urine before necropsy and blood at euthanasia, then harvest kidneys for histopathology and molecular analysis.

• Analyze serum creatinine and BUN, urinary biomarkers, urinary protein/glucose/alkaline phosphatase when selected, and renal tissue sections for tubular injury, degeneration, necrosis, or biomarker staining.

• Interpret nephrotoxicity using concordance between renal function markers, urinary or tissue injury biomarkers, and histopathology.

• KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, and Oat5 can change earlier than serum creatinine or BUN in several rodent nephrotoxicity models, but biomarker performance varies by model, dose, timing, species, and injury severity.

• Use vehicle-treated animals as negative controls and nephrotoxicant-treated animals as positive injury controls.

• Include histopathology as the tissue-level comparator when evaluating biomarker performance, because multiple cited studies compared biomarker changes with renal lesions.

Problem: Serum creatinine and BUN remain unchanged despite suspected early kidney injury.

• Possible Cause: Functional markers may rise later than tubular injury biomarkers.
• Literature-supported Solution: Add urinary or tissue KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, or Oat5 measurements and align sampling with early time points used in the selected model.

Problem: A biomarker signal is weak or inconsistent.

• Possible Cause: Biomarker sensitivity depends on toxicant, dose, timing, and injury severity.
• Literature-supported Solution: Confirm injury with renal histopathology and use a panel rather than a single biomarker when the model supports multiple readouts.

Problem: In vitro gentamicin exposure does not reproduce in vivo KIM-1 or NGAL induction.

• Possible Cause: HK-2 cells treated with gentamicin up to 48 h did not show significant biomarker gene or protein increases in one study.
• Literature-supported Solution: Use the in vivo gentamicin rat model for KIM-1/NGAL nephrotoxicity detection rather than relying on that in vitro endpoint.